1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Aug 2024
Admin
News Article

Valneva and Limmatech Biologics Partner to Advance Shigella Vaccine Candidate

Overview

Valneva and LimmaTech Biologics have entered into a strategic partnership and exclusive licensing agreement aimed at accelerating the development of a Shigella vaccine candidate.

No vaccine- There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally.

Problem for kids- It places a particularly high burden on children in low- and middle-income countries (LMICs), and the development of Shigella vaccines has been identified as a priority by the World Health Organization.

Exclusive Global Licence

The new agreement gives Valneva an exclusive global licence for LimmaTech’s Shigella4V, a tetravalent bioconjugate vaccine that has already shown promise in a phase 1/2 trial.

Interim Data for Pathogenic Shigella Serotypes

According to interim data from the study shared by the biotech earlier this year, the candidate demonstrated a favourable safety and tolerability profile as well as significant immunogenicity against the four most common pathogenic Shigella serotypes.

Phase 2 Study for Vaccine in LMICs

LimmaTech will now conduct a phase 2 controlled human infection model and a phase 2 paediatric study of the vaccine in LMICs, which are both expected to begin later this year, while Valneva will assume all further development and regulatory activities and will be responsible for its commercialisation globally if approved.

In exchange, LimmaTech will receive an upfront payment of €10m and will be eligible for additional regulatory, development and sales-based milestone payments, as well as low double-digit royalties on sales.

Words from CEO: Valneva

Valneva’s chief executive officer, Thomas Lingelbach, said: “We are very pleased to partner with LimmaTech to advance a promising programme in an area of high unmet medical need.
The Shigella vaccine candidate enables a potential first-in-class vaccine solution for both LMICs and travellers and, as such, represents a potentially highly synergistic product for Valneva.

LimmaTech initiated Shigella4V and continued to lead its development as part of its ongoing collaboration with GSK, which it later in-licensed the candidate from.

Latest Agreement on Vaccine

Commenting on the latest agreement for the vaccine, Dr Franz-Werner Haas, the company’s chief executive officer, said: Having developed the S4V Shigella vaccine candidate from its early discovery phase to the promising clinical data we achieved to date, we are excited to accelerate the programme with our partnership with Valneva.
[Its] proven expertise in late-stage development and commercialisation of vaccines will expedite potential market approval and bring a Shigella vaccine to people in need.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!